Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Global-Ig: a population-based antibody library technique to optimize the development of globally protective vaccines

Project description

Global-lg technique for population-based vaccine development

The SARS-CoV-2 pandemic underscored the need for vaccines that offer protection across diverse populations. Variability in human antibody genes influences immune responses, making it essential to understand potential differences in how humans recognise vaccine candidates. The ERC-funded GlobalPROTECT project will develop a technique called Global-Ig to generate large antibody libraries representing naive B cell repertoires from different populations. These will be used to evaluate B cell recognition of vaccine candidates and identify widely recognised antigens. If an antibody library from a certain population displays suboptimal recognition of a vaccine antigen, the antigen can be modified to better accommodate this genetic difference. This approach enables pre-screening and selection of suitable antigens before a vaccine candidate goes through clinical trials, reducing costs and advancing health equity.

Objective

As the SARS-CoV-2 pandemic has demonstrated, vaccines that provide broad global protection are needed. However, human antibody genes are highly variable and thus, the quality of vaccine-induced responses can vary between population groups. This variation is shaped by the long history of host/disease interactions and differences in endemic diseases between regions over time, resulting in differences in antibody allele frequencies between populations. Therefore, information about how naïve antibody repertoires representing diverse population groups recognize vaccine candidates would greatly improve the development of broadly protective vaccines. In this Proof-of-Concept grant, we will develop a technique, Global-Ig, which allows in vitro production of large antibody libraries from a database of antibody germline gene variants representing the range of human global variation observed in the major population groups of the world, which we have assembled as part of our ongoing ERC Advanced project. Libraries representing different population groups will be used to prospectively identify differences in B cell recognition of candidate vaccines to facilitate selection of vaccine antigens that are broadly recognized. In cases where suboptimal binding to a vaccine antigen is detected for one or more population groups, the antigen can be modified to better accommodate population-specific alleles. Importantly, prospective screening against population-based antibody libraries in vitro offers possibilities to identify antigens that are broadly recognized prior to advancing candidates to clinical trials, substantially reducing costs associated with clinical development and improving health equity. Thus, the population-based Global-Ig antibody library technique described here represents an opportunity to harness information about human antibody germline gene variation gained in our ongoing ERC Advanced grant to select and tailor vaccine candidates for a global market.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

KAROLINSKA INSTITUTET
Net EU contribution
€ 45 000,00
Address
NOBELS VAG 5
171 77 STOCKHOLM
Sweden
Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (2)